(Q55069844)

16 June 2018

title

The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model. (English)

1 reference

16 June 2018

main subject

pp-242

1 reference

ChEBI release 2020-05-28

1 reference

Xiaohua Zhang

1

1 reference

16 June 2018

Xianjin Wang

2

1 reference

16 June 2018

Liang Qin

3

1 reference

16 June 2018

Tianyuan Xu

4

1 reference

16 June 2018

Zhaowei Zhu

5

1 reference

16 June 2018

Shan Zhong

6

1 reference

16 June 2018

Minguang Zhang

7

1 reference

16 June 2018

Zhoujun Shen

8

1 reference

16 June 2018

language of work or name

English

0 references

publication date

6 November 2014

1 reference

16 June 2018

published in

Urology

1 reference

16 June 2018

volume

85

1 reference

16 June 2018

issue

1

1 reference

16 June 2018

page(s)

273.e1-7

1 reference

16 June 2018

Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Rapamycin passes the torch: a new generation of mTOR inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

The antiproliferative effects of ouabain and everolimus on adrenocortical tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

The pharmacology of mTOR inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Rapamycin inhibits mTORC1, but not completely.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Mechanisms of mTOR inhibitor resistance in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

mTOR: from growth signal integration to cancer, diabetes and ageing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

An expanding role for mTOR in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Where is mTOR and what is it doing there?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

mTOR kinase inhibitors as potential cancer therapeutic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

mTOR signaling at a glance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

Interferon alpha and rapamycin inhibit the growth of pheochromocytoma PC12 line in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.09.020

10.1016/J.UROLOGY.2014.09.020

7 January 2021

Identifiers

DOI

1 reference

16 June 2018

1 reference

16 June 2018